ArticleNanomaterials (Basel, Switzerland)2022
ROS- and pH-Responsive Polydopamine Functionalized Ti
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Synthesis and advanced applications of MXene nanosheets in energy storage, EMI shielding, and biomedicine: a review.RSC advances · 2026Review
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Surface Engineering of MXenes for Biomedical Uses: Functionalization Strategies and Application Trends.Biomaterials research · 2026Review
- Biocompatibility and immunomodulation of MXenes for targeted delivery of bioactive agents and drugs.Bioactive materials · 2026Review
- Sol-Gel Engineered MXene/FeGels (Basel, Switzerland) · 2025Article
- Guides for Developing Hundreds of Novel Chiral MXenes and MBenes Nanosheets/Quantum Dots for Next-Generation Chiral Engineered Biomaterials Applications.Advanced healthcare materials · 2025Review
- Immune-mediated interactions between sarcopenia and atherosclerosis in aging.Immunity & ageing : I & A · 2025Review
- CD11b-modified ROS/pH-responsive nanoparticles co-deliver Dioscin and siRNA to improve cardiac repair after myocardial infarction by reducing neutrophil recruitment.Materials today. Bio · 2025Article
- Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy.Materials (Basel, Switzerland) · 2025Review
- MXenes in the application of diabetic foot: mechanisms, therapeutic implications and future perspectives.Journal of materials science. Materials in medicine · 2025Review
- MXene-Integrated Composites for Biomedical Applications: Synthesis, Cancer Diagnosis, and Emerging Frontiers.Small science · 2025Review
- Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.Pharmaceutics · 2024Review
- Nanosomes in Precision Nanomedicine.Nanomaterials (Basel, Switzerland) · 2024Article
- 2D MXene Nanosheets with ROS Scavenging Ability Effectively Delay Osteoarthritis Progression.Nanomaterials (Basel, Switzerland) · 2024Article
- MXene-based composites in smart wound healing and dressings.Nanoscale advances · 2024Review
- Research Progress on TiMolecules (Basel, Switzerland) · 2024Review
- TiJournal of nanobiotechnology · 2024Article
- Polydopamine-Based Biomaterials in Orthopedic Therapeutics: Properties, Applications, and Future Perspectives.Drug design, development and therapy · 2024Review
- MXene: A wonderful nanomaterial in antibacterial.Frontiers in bioengineering and biotechnology · 2024Review
- Doxorubicin-Loaded Fungal-Carboxymethyl Chitosan Functionalized Polydopamine Nanoparticles for Photothermal Cancer Therapy.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Premature drug release and poor controllability is a challenge in the practical application of tumor therapy, which may lead to poor chemotherapy efficacy and severe adverse effects. In this study, a reactive oxygen species (ROS)-cleavable nanoparticle system (MXene-TK-DOX@PDA) was designed for effective chemotherapy drug delivery and antibacterial applications. Doxorubicin (DOX) was conjugated to the surface of (3-aminopropyl)triethoxysilane (APTES)-functionalized MXene via an ROS-cleavable diacetoxyl thioketal (TK) linkage. Subsequently, the surfaces of the MXene nanosheets were coated with pH-responsive polydopamine (PDA) as a gatekeeper. PDA endowed the MXene-TK-DOX@PDA nanoparticles with superior biocompatibility and stability. The MXene-TK-DOX@PDA nanoparticles had an ultrathin planar structure and a small lateral size of approximately 180 nm. The as-synthesized nanoparticles demonstrated outstanding photothermal conversion efficiency, superior photothermal stability, and a remarkable extinction coefficient (23.3 L g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.